Incidence and determinants of severe morbidity among HIV-infected patients from Rio de Janeiro, Brazil, 2000-2010

Antiviral Therapy

Volumn 19, Issue 4, 2014, Pages 387-397

  Ribeiro, Sayonara R ^a   Luz, Paula M ^a   Campos, Dayse P ^a   Moreira, Ronaldo I ^a   Coelho, Lara ^a   Japiassu, André ^a   Bozza, Fernando ^a   Veloso, Valdilea G ^a   Chene, Genevieve ^b   Grinsztejn, Beatriz ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; ALLERGIC REACTION; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BRAZIL; CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; CD4 LYMPHOCYTE COUNT; CONGESTIVE HEART FAILURE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PNEUMOCYSTOSIS; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SEX RATIO; SYSTEMIC DISEASE; THROMBOSIS; TOXOPLASMOSIS; TUBERCULOSIS; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; HEALTH SURVEY; HISTORY; HIV INFECTIONS; MIDDLE AGED; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BRAZIL; FEMALE; HISTORY, 21ST CENTURY; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MORBIDITY; PREVALENCE; PUBLIC HEALTH SURVEILLANCE; RISK FACTORS; YOUNG ADULT;

EID: 84919804157     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2716     Document Type: Article

References (30)

1. The Antiretroviral Therapy Cohort Collaboration. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38:1624-1633.
2. Berry SA, Fleishman JA, Moore RD, Gebo KA. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008. J Acquir Immune Defic Syndr 2012; 59:368-375.
3. The Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-1396.
4. Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55:262-270.
5. Pacheco AG, Tuboi SH, May SB, et al. Temporal changes in causes of death among HIV-infected patients in the HAART era in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 2009; 51:624-630.
6. Belloso WH, Orellana LC, Grinsztejn B, et al. Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites. HIV Med 2010; 11:554-564.
7. Buchacz K, Baker RK, Moorman AC, et al. Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005. AIDS 2008; 22:1345-1354.
8. Yehia BR, Fleishman JA, Wilson L, Hicks PL, Gborkorquellie TT, Gebo KA. Incidence of and risk factors for bacteraemia in HIV-infected adults in the era of highly active antiretroviral therapy. HIV Med 2011; 12:535-543.
9. Bonnet F, Chene G, Thiebaut R, et al. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med 2007; 8:547-554.
10. Grinsztejn B, Veloso VG, Friedman RK, et al. Early mortality and cause of deaths in patients using HAART in Brazil and the United States. AIDS 2009; 23:2107-2114.
11. Grinsztejn B, Veloso VG, Pilotto JH, Campos DP, Keruly JC, Moore RD. Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil. J Acquir Immune Defic Syndr 2007; 45:515-520.
12. Moreira RI, Luz PM, Struchiner CJ, et al. Immune status at presentation for HIV clinical care in Rio de Janeiro and Baltimore. J Acquir Immune Defic Syndr 2011; 57 Suppl 3:S171-S178.
13. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73:13-22.
14. Ballinger GA. Using generalized estimating equations for longitudinal data analysis. Organ Res Methods 2004; 7:127-150.
15. Crum-Cianflone NF, Grandits G, Echols S, et al. Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use? J Acquir Immune Defic Syndr 2010; 54:248-257.
16. Mocroft A, Monforte A, Kirk O, et al. Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Med 2004; 5:437-447.
17. Ministério da Saúde, Brazil. [Recomendações para terapia anti-retroviral em adultos infectados pelo HIV. Programa Nacional de DST e AIDS.] Secretaria de Vigilância em Saúde. Ministério da Saúde. (Updated 23 October 2007. Accessed 20 March 2013.) Available from http://www.aids.gov.br/publicacao/recomendacoes-para- terapia-antirretroviral-em-adultos-infectados-pelo-hiv-2008. Portuguese.
18. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53:323-332.
19. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomised controlled trial. Lancet 2007; 369:1261-1269.
20. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395-402.
21. DeJesus E, Rockstroh JK, Lennox JL, et al. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. HIV Clin Trials 2012; 13:228-232.
22. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV Cohort Study. Clin Infect Dis 2011; 53:1130-1139.
23. Anglaret X, Minga A, Gabillard D, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Côte d'Ivoire. Clin Infect Dis 2012; 54:714-723.
24. Sogaard OS, Lohse N, Gerstoft J, et al. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis 2008; 47:1345-1353.
25. Japiassú AM, Amancio RT, Mesquita EC, et al. Sepsis is a major determinant of outcome in critically ill HIV/AIDS patients. Crit Care 2010; 14:R152.
26. Cardoso SW, Grinsztejn B, Velasque L, et al. Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil. AIDS Res Hum Retroviruses 2010; 26:865-874.
27. Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis 2009; 48:633-639.
28. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425-432.
29. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21:3447-3453.
30. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 2009; 23:41-50.